The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Virus-like particles in vaccine development
Abstract
Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H., & Gillison, M. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065497 · Cited by 2,692
Chapter 2: The burden of HPV-related cancers
Parkin, D. M., & Bray, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.111 · Cited by 1,385
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein
Jiang, X., Wang, M., Graham, D. Y., & Estes, M. K. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6527-6532.1992 · Cited by 860
Global control of hepatitis B virus infection
Kao, J.-H., & Chen, D.-S. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00315-8 · Cited by 805
A universal influenza A vaccine based on the extracellular domain of the M2 protein
Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M., & Fiers, W. (1999) · Nature Medicine · doi:10.1038/13484 · Cited by 752
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11553 · Cited by 668
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Robilotti, E., Deresinski, S., & Pinsky, B. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00075-14 · Cited by 589
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
Construction and Characterization of Virus-Like Particles: A Review
Zeltins, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-012-9598-4 · Cited by 478
Design of a hyperstable 60-subunit protein icosahedron
Hsia, Y., Bale, J. B., Gonen, S., Shi, D., Sheffler, W., Fong, K. K., Nattermann, U., Xu, C., Huang, P.-S., Ravichandran, R., et al. (2016) · Nature · doi:10.1038/nature18010 · Cited by 445
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Brune, K. D., Leneghan, D. B., Brian, I. J., Ishizuka, A. S., Bachmann, M. F., Draper, S. J., Biswas, S., & Howarth, M. (2016) · Scientific Reports · doi:10.1038/srep19234 · Cited by 412
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Abd El-Aziz, T. M., & Stockand, J. D. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104327 · Cited by 363
Bioengineering virus‐like particles as vaccines
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25159 · Cited by 355
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M. H., Turner, D. L., & Turner, R. J. (2021) · Vaccines · doi:10.3390/vaccines9050467 · Cited by 339
Carbohydrate-Based Macromolecular Biomaterials
Su, L., Feng, Y., Wei, K., Xu, X., Liu, R., & Chen, G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01338 · Cited by 335
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Production of virus-like particles for vaccines
Fuenmayor, J., Gòdia, F., & Cervera, L. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.07.010 · Cited by 318
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies
Rawat, K., Kumari, P., & Saha, L. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173751 · Cited by 276
Protein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Large-scale production and purification of VLP-based vaccines
Vicente, T., Roldão, A., Peixoto, C., Carrondo, M. J. T., & Alves, P. M. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.004 · Cited by 270
Self-citationNext‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery
Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Bahar, M. W., Porta, C., Fox, H., Macadam, A. J., Fry, E. E., & Stuart, D. I. (2021) · npj Vaccines · doi:10.1038/s41541-020-00267-3 · Cited by 42
A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice
Dai, W., Zhang, C., Zhang, X., Xiong, P., Liu, Q., Gong, S., Geng, L., Zhou, D., & Huang, Z. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.057 · Cited by 46
Hennrich, A. A., Sawatsky, B., Santos-Mandujano, R., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Riedel, C., Pfaller, C. K., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009064 · Cited by 30
Metadata
- Authors
- Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2010-10
- Volume
- 9
- Issue
- 10
- Pages
- 1149-1176
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2149913957
- Cited by
- 845
- References
- 154
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.